US lawmakers now want to hear from the middlemen PBMs to unpack their role in drug pricing
The US Senate Finance Committee is upping the ante on the issue of drug pricing with yet another hearing — this time with pharmacy benefit managers, the middlemen that negotiate rebates with drugmakers in exchange for formulary coverage and the purported villains behind skyrocketing list prices (according to big Pharma) in a hearing last month.
On Tuesday, Senators Chuck Grassley and Ron Wyden invited executives from five PBMs — Cigna, CVS, Humana, UnitedHealth’s OptumRx and Prime Therapeutics — to testify on April 3 in the third drug pricing hearing this year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.